 | | Vol. 16.08 – 29 February, 2024 |
| |
|
|
| Investigators discovered that hypoxia promoted breast cancer metastasis through suppression of ΔNp63α in a hypoxia-inducible factor 1 α (HIF1α)-independent manner.
[Cell Death & Differentiation] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists reported the development of a second-generation AKT degrader which outperformed catalytic AKT inhibition with respect to cellular suppression of AKT-dependent phenotypes in breast cancer cell lines.
[Science Signaling] |
|
|
|
| Researchers revealed that spatial coincidence of abundant cancer-associated fibroblasts infiltration with malignant cells was associated with reduced estrogen receptor-α expression and activity in luminal breast tumors.
[Oncogene] |
|
|
|
| Investigators reported that transforming growth factor β (TGF-β) enhanced HER2 activation, leading to the activation of mitogen-activated protein kinase and AKT.
[Journal Of Cell Biology] |
|
|
|
| Using functional assays, scientists demonstrated that solute carrier family 25 (SLC25) A17 knockdown suppressed proliferation, epithelial-mesenchymal transition, migration, and invasion.
[Cancer Cell International] |
|
|
|
| Researchers investigated the microRNA-203a regulatory mechanisms and their potential functions in the progress of breast cancer.
[Scientific Reports] |
|
|
|
| Through the analysis of large-throughput biological data of breast tumors, combined with the characteristics of the biological process of ferroptosis, the specific gene isocitrate dehydrogenase 2 was found to be significantly highly expressed in TNBC and functionally correlated with ferroptosis.
[Scientific Reports] |
|
|
|
| Investigators evaluated the role of estrogen-related receptor alpha in the migration, invasion and angiogenesis of breast cancer stem cells.
[Medical Oncology] |
|
|
|
|
| Researchers evaluate the utilization strategies of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) across various subpopulations of breast cancer and explore potential therapeutic avenues following disease progression during the application of CDK4/6i therapy.
[Cancer Gene Therapy] |
|
|
|
|
| Dr. White-Means received a one and a half million, four-year grant from the National Institute on Minority Health and Health Disparities to explore the intersectionality of race, residential segregation, and poverty as a driver of health disparities in breast cancer.
[University of Tennessee Health Science Center] |
|
|
|
| Congratulations to the BC Cancer researchers who are recipients of the 2023 Canadian Cancer Society Challenge Grants Competition. The grants provided support to cancer research projects with the ultimate goal of solving a problem in cancer that is meaningful to people affected by or at risk of cancer.
[BC Cancer Research] |
|
|
|
|
| April 7 – 10, 2024
San Diego, California, United States |
|
|
|
|
|
| | Montreal Clinical Research Institute – Montréal, Québec, Canada |
|
|
|
| | Augusta University – Augusta, Georgia, United States |
|
|
|
| | Cedars Sinai Medical Center – Los Angeles, California, United States |
|
|
|
| | UC Davis – Davis, California, United States |
|
|
|
| | Cyprus Cancer Research Institute – Aglandjia, Cyprus |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
